-
Subject Areas on Research
-
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
-
A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
-
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
-
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
-
A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients.
-
A mouse model for heparin-induced thrombocytopenia.
-
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
-
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
-
A national study of the complications of lupus in pregnancy.
-
A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families.
-
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
-
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
-
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
-
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
-
A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia.
-
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
-
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
-
A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants.
-
A rapid method to isolate platelets from human blood by density gradient centrifugation.
-
ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype.
-
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.
-
ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?
-
Abciximab readministration: results of the ReoPro Readministration Registry.
-
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
-
Acute profound thrombocytopenia after c7E3 Fab therapy.
-
Adding to the Denominator: A Case Report of Neuraxial Anesthesia for Cesarean Delivery in the Setting of Hemolysis, Elevated Liver Enzyme, Low Platelet, Thrombocytopenia, and Pulmonary Hypertension.
-
Adjunctive agents in systemic chemotherapy.
-
Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.
-
Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study.
-
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.
-
Alloimmune thrombocytopenia may be associated with systemic disease.
-
Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
-
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
-
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
-
Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
-
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
-
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.
-
Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.
-
Anticoagulation techniques in apheresis: from heparin to citrate and beyond.
-
Anticoagulation therapy.
-
Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome.
-
Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.
-
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
-
Argatroban for anticoagulation during cardiopulmonary bypass in an infant.
-
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
-
Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
-
Atomic description of the immune complex involved in heparin-induced thrombocytopenia.
-
Authors' response to thrombocytopenia following exchange transfusion in neonates.
-
Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13.
-
Beta-lactam antibiotic-induced pseudoporphyria.
-
Beyond thrombosis: the versatile platelet in critical illness.
-
Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia.
-
Bilateral macular vitelliform lesions in a thrombocytopenic patient.
-
Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
-
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
-
Bivalirudin: a review of the pharmacology and clinical application.
-
Bleeding in acute coronary syndromes.
-
Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia.
-
Can HIT testing lose its radioactivity?
-
Cangrelor and Heparin for Pulmonary Thromboendarterectomy in Heparin-Induced Thrombocytopenia.
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
-
Capsule endoscopy performed across the pediatric age range: indications, incomplete studies, and utility in management of inflammatory bowel disease.
-
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
-
Case records of the Massachusetts General Hospital. Case 21-2005. A four-week-old male infant with jaundice and thrombocytopenia.
-
Cesarean delivery for fetal malformations.
-
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.
-
Chronic immune-mediated thrombocytopenia after varicella infection.
-
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
-
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
-
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
-
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.
-
Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia.
-
Clinical practice. Heparin-induced thrombocytopenia.
-
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
-
Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.
-
Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
-
Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients.
-
Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia.
-
Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.
-
Congenital hemophagocytic lymphohistiocytosis presenting as thrombocytopenia in a newborn.
-
Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.
-
Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients.
-
Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin.
-
Critical role for mouse marginal zone B cells in PF4/heparin antibody production.
-
Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.
-
Cytomegalovirus infection in the normal host.
-
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
-
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.
-
Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.
-
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
-
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction.
-
Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think.
-
Diagnosis and management of heparin-induced thrombocytopenia.
-
Diagnosis and management of heparin-induced thrombocytopenia.
-
Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura.
-
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).
-
Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.
-
Diuretic exposure in premature infants from 1997 to 2011.
-
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
-
Dose of prophylactic platelet transfusions and prevention of hemorrhage.
-
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
-
Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation.
-
Dynamic antibody-binding properties in the pathogenesis of HIT.
-
Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia.
-
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
-
Economic assessment of thrombocytopenia: CATCH Registry.
-
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
-
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
-
Efficacy of abciximab readministration in coronary intervention.
-
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
-
Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications.
-
Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.
-
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
-
Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.
-
Etiology and complications of thrombocytopenia in hospitalized medical patients.
-
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
-
Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay.
-
Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
-
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
-
Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic.
-
Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML).
-
Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia.
-
Fatal Rocky Mountain spotted fever. Hematologic and lymphoreticular observations.
-
Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.
-
Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.
-
Feasibility and safety of moderate hypothermia after massive hemispheric infarction.
-
Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.
-
Final results of the ReoPro readministration registry.
-
Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II.
-
Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis.
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
-
Genome-Wide Association Study Links Receptor Tyrosine Kinase Inhibitor Sprouty 2 to Thrombocytopenia after Coronary Artery Bypass Surgery.
-
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
-
Genotype-phenotype correlation in MYH9-related thrombocytopenia.
-
Graft-v-host disease is associated with autoimmune-like thrombocytopenia.
-
HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia.
-
HIV-1-associated thrombocytopenia. The role of splenectomy.
-
Hematologic findings in a large sample of patients with anorexia nervosa and bulimia nervosa.
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
-
Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.
-
Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists.
-
Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients.
-
Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients.
-
Heparin-induced Thrombocytopenia: Perioperative Diagnosis and Management.
-
Heparin-induced thrombocytopenia and cardiac surgery.
-
Heparin-induced thrombocytopenia and thrombosis.
-
Heparin-induced thrombocytopenia in cancer.
-
Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.
-
Heparin-induced thrombocytopenia in the pediatric intensive care unit population.
-
Heparin-induced thrombocytopenia presenting as unilateral lower limb paralysis following lumbar spine surgery: case report.
-
Heparin-induced thrombocytopenia, a prothrombotic disease.
-
Heparin-induced thrombocytopenia.
-
Heparin-induced thrombocytopenia.
-
Heparin-induced thrombocytopenia.
-
Heparin-induced thrombocytopenia.
-
Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.
-
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
-
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
-
Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery.
-
Heparin-induced thrombocytopenia: clinical presentations and therapeutic management.
-
Heparin-induced thrombocytopenia: research and clinical updates.
-
Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
-
Hereditary thrombotic thrombocytopenic purpura: microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurring in consecutive generations.
-
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.
-
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
-
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.
-
High-dose intravenous methylprednisolone for Kasabach-Merritt syndrome.
-
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
-
How I treat catastrophic thrombotic syndromes.
-
How I treat thrombocytopenia in pregnancy.
-
How Low Is Too Low? Postpartum Hemorrhage Risk among Women with Thrombocytopenia.
-
How low did we go? A case report of unexpected thrombocytopenia.
-
Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration.
-
Hypercoagulable states: a review.
-
IVIG therapy in neonatal isoimmune thrombocytopenic purpura and alloimmunization thrombocytopenia.
-
Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee.
-
Idiopathic monoclonal (IgA) gammopathy in a dog.
-
Immune fever in the rabbit: responses of the hematologic and complement systems.
-
Immune pathogenesis of heparin-induced thrombocytopenia.
-
Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children?
-
Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters.
-
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
-
Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group.
-
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.
-
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
-
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
-
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
-
Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis.
-
Inflammation does not predispose to bleeding in hemophilia.
-
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
-
Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis.
-
Interference of thrombin in immunological assays for hirudin specific antibodies.
-
International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis.
-
Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?
-
Isoantibody specificity in post-transfusion purpura.
-
Isolated thrombocytopenia associated with oral terbinafine.
-
Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study.
-
Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine.
-
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome.
-
Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report.
-
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
-
Management of human immunodeficiency virus-associated thrombocytopenia with intravenous gamma globulin.
-
Management of immune dysfunction after adult cardiac surgery.
-
Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
-
Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia.
-
Minimal role for the alternative pathway in complement activation by HIT immune complexes.
-
Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia.
-
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
-
Monitoring direct thrombin inhibitors: time for standardization.
-
Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
-
Mullerian agenesis and thrombocytopenia absent radius syndrome: a case report and review of syndromes associated with Mullerian agenesis.
-
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
-
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.
-
Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.
-
Myelotoxicity from chemotherapy.
-
Natural history of nonimmune-mediated thrombocytopenia and acute kidney injury in pediatric open-heart surgery.
-
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
-
Neutrophil accumulation and NET release contribute to thrombosis in HIT.
-
New treatment options for heparin-induced thrombocytopenia.
-
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
-
Novel diagnostic assays for heparin-induced thrombocytopenia.
-
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
-
Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
-
PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses.
-
PF4/heparin complexes are T cell-dependent antigens.
-
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.
-
Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
-
Pathogenesis of heparin-induced thrombocytopenia and thrombosis.
-
Pathogenesis of heparin-induced thrombocytopenia.
-
Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin.
-
Paving the way for improved management of severe immune thrombocytopenia purpura in pregnancy.
-
Pearls & Oy-sters: multiple ischemic strokes secondary to heparin-induced thrombocytopenia.
-
Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens.
-
Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
-
Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies.
-
Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.
-
Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.
-
Peripheral serotonin causes dengue virus-induced thrombocytopenia through 5HT2 receptors.
-
Persistent thrombocytopaenia in a young man with splenomegaly, rebound thrombocytosis after splenectomy and subsequent pulmonary embolism: splenic littoral cell angioma and associated events.
-
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
-
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
-
Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma.
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
-
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
-
Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
-
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
-
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
-
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
-
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
-
Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.
-
Plasma thrombopoietic activity in humans with normal and abnormal platelet counts.
-
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.
-
Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT).
-
Platelet count in deep saturation diving.
-
Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway.
-
Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional.
-
Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes.
-
Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome.
-
Posttransfusion thrombocytopenia: a cautionary tale of female group AB plasma.
-
Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation.
-
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
-
Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.
-
Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome.
-
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
-
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
-
Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia.
-
Protamine-induced immune thrombocytopenia.
-
RNA aptamers as reversible antagonists of coagulation factor IXa.
-
Rattlesnake venom-induced thrombocytopenia response to Antivenin (Crotalidae) Polyvalent: a case series.
-
Readministration of abciximab: interim report of the ReoPro readministration registry.
-
Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.
-
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
-
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia.
-
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
-
Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.
-
Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity.
-
Report of a young girl with MYH9 mutation and review of the literature.
-
Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma.
-
Rifampin use and safety in hospitalized infants.
-
Risk of Epidural Hematoma after Neuraxial Techniques in Thrombocytopenic Parturients: A Report from the Multicenter Perioperative Outcomes Group.
-
Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses.
-
Roentgenographic abnormalities in Rocky Mountain Spotted Fever.
-
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
-
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
-
SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia.
-
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.
-
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
-
Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections.
-
Safety of milrinone use in neonatal intensive care units.
-
Safety of octreotide in hospitalized infants.
-
Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
-
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
-
Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients.
-
Silencing Porcine CMAH and GGTA1 Genes Significantly Reduces Xenogeneic Consumption of Human Platelets by Porcine Livers.
-
Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).
-
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
-
Techniques and applications of perioperative therapeutic plasma exchange.
-
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.
-
The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices.
-
The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on Neuraxial Procedures in Obstetric Patients With Thrombocytopenia.
-
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
-
The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).
-
The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.
-
The effect of drug-induced thrombocytopenia on direct-current transcatheter electrocoagulation.
-
The fate of human platelets exposed to porcine renal endothelium: a single-pass model of platelet uptake in domestic and genetically modified porcine organs.
-
The hematological effects of nitrous oxide anesthesia in pediatric patients.
-
The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia.
-
The relationship of complement consumption to immune fever.
-
The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia.
-
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
-
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia.
-
The scientific basis for evaluation and management of thrombotic disorders.
-
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
-
Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: A systematic review.
-
Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey.
-
Thrombocytopenia and absent radii (TAR) syndrome associated with horseshoe kidney.
-
Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.
-
Thrombocytopenia in allogeneic peripheral blood stem cell collections.
-
Thrombocytopenia in association with a wandering spleen.
-
Thrombocytopenia in hospitalized patients with severe clostridium difficile infection.
-
Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]).
-
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.
-
Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination.
-
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
-
Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors.
-
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
-
Treatment of patients with pineoblastoma with high dose cyclophosphamide.
-
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.
-
Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9-related disorders.
-
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
-
Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors.
-
Use of therapeutic plasma exchange in heparin-induced thrombocytopenia: A population-based study.
-
Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia.
-
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.
-
Vincristine therapy for severe platelet alloimmunization.
-
Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas.
-
What is the evidence for platelet transfusion in perioperative settings?
-
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.
-
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes].
-
[Malignant melanoma: hepatic intra-arterial chemotherapy].
-
Keywords of People
-
Arepally, Gowthami Morey,
Professor of Medicine,
Pathology
-
Granger, Christopher Bull,
Professor of Medicine,
School of Nursing
-
Hoffman, Maureane,
Professor of Pathology,
Immunology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Stinnett, Sandra Sue,
Associate Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Yoo, Sua,
Associate Professor of Radiation Oncology,
Radiation Oncology